secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001213900-26-003998
Event type: regulatory
Sentiment:  negative
Materiality: 0.35
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma receives Nasdaq deficiency notice for failure to hold annual meeting
--------------------------------------------------------------------------------

- Received Nasdaq letter on Jan 7, 2026, citing non-compliance with Listing Rule 5620(a) for not holding annual meeting.
- Company has 45 calendar days to submit a plan to regain compliance.
- Expects to convene annual meeting in April 2026 and will consult with Nasdaq on compliance.
- No immediate impact on listing or trading of ESLA common stock or ESLAW warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390026003998/0001213900-26-003998-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390026003998/ea027282201-8k_estrellaimmu.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-003998

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer